FDA warns Salix on omitting risks and broadening indication for Metozolv
This article was originally published in Scrip
The US FDA has sent Salix Pharmaceuticals a warning letter, stating that certain promotional materials – including a "Now Approved" journal launch ad - for Metozolv ODT are false and misleading because "they omit and minimise risk information, broaden the indication… and contain unsubstantiated comparative and other claims". Metozolv ODT, an orally disintegrating formulation of metoclopramide HCl, was approved last September to treat short-term refractory gastroesophageal reflux disease (GORD) and diabetic gastroparesis, and made available to pharmacies in November (scripnews.com, 14 September 2009).
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.